课题基金 / 基金详情

Concise Syntheses of the Meroterpenoids: Facilitating the Discovery of New Classes of Pharmaceuticals

Concise Syntheses of the Meroterpenoids: Facilitating the Discovery of New Classes of Pharmaceuticals
类萜的简明合成:促进新型药物的发现
批准号:
EP/N022815/1
负责人:
Tony Barrett
金额:
$56.66万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --

项目摘要

项目成果

Tony Barrett的其他基金

相似基金

相关文献

中文摘要
翻译
在英国和全球范围内,癌症和传染病是造成相当大的发病率和死亡率的原因。这两种疾病的耐药性尤其令人担忧,因为当患者对现有疗法没有反应时,预后往往很糟糕。例如,在英国和美国最常见的癌症是乳腺癌。美国国家癌症研究所(National Cancer Institute)公布了2015年美国乳腺癌新病例的统计数据,估计为234,190例,其中40,700例死亡[http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf]]。英国癌症研究中心也公布了英国的统计数据,2011年有331487例新诊断的癌症,其中乳腺癌、前列腺癌、肺癌和肠癌占了一半以上。在同一篇文章中,作者报告了2011年50,285例乳腺癌新病例和11,716例乳腺癌死亡[http://www.cancerresearchuk.org/health-professional/cancer-statistics#heading-Zero]]。包括乳腺癌在内的许多癌症患者对治疗期间使用的药物产生耐药性。例如,接受治疗的患者中约有25%出现他莫昔芬耐药性。他莫昔芬是乳腺组织中雌激素受体的拮抗剂,在乳腺癌治疗中具有相当重要的作用。在传染病领域,一般媒体广泛报道细菌对常见抗生素的耐药性,令人痛苦地报道了万古霉素耐药肠球菌或耐甲氧西林金黄色葡萄球菌感染,其临床表现为坏死性筋膜炎(食肉病)。患者群体中出现耐药性是发现和开发治疗癌症和其他疾病中的细菌感染的新药的主要推动力。2014年,Vertex公司的科学家[http://pubs.acs.org/doi/abs/10.1021/jm500941m]]报告说,天然产品再次非常适合通过化学转化来研究和衍生,以制备新的生物活性化合物,用于分析和优化,作为未来的抗癌剂和抗生素。在这篇文章中,他们报告说,从1981年1月到2010年12月,引进的1073种新药中有540种是天然产物,天然产物的衍生物或与天然产物结构相关(生物启发),但由化学合成而成。通过例子,作者描述了多西他赛的天然产物先导物的重要性,多西他赛是紫杉醇的衍生物,用于治疗各种癌症,Ixabepilone是用于治疗紫杉醇耐药癌症的艾泊thilone B的类似物,以及许多其他例子。这项研究计划的重点是设计和开发四种新的化学转化,这些转化是在帝国理工学院发明的,用于合成一类天然产物,美罗萜类化合物。巯基萜类化合物是一类结构多样的化合物,具有多种生物活性,可作为抗生素和抗癌药物等。一般来说,这些化合物是有活性的,但它们本身的活性不足以成为药物。在医药术语中,它们是命中,而不是先导。为了使合成复杂的天然产物(如甲硫萜类化合物)具有实用性,有必要使合成路线短,并且能够根据生物测定结果和计算机辅助药物设计指导平行合成,以产生药物先导。帝国理工学院的研究小组现在有了必要的合成工具来进行结构活性研究,并将基于美罗萜类化合物的新药发现触手可及。在这项研究中,新的帝国化学反应将与其他转化一起使用,包括选择性氧化和环化反应(形成额外的环),以开辟美罗萜类化合物的合理药物化学和药物发现领域。
英文摘要
Cancer and infectious disease are the cause of very considerable morbidity and mortality in the UK and globally. Resistance with both diseases is of particular concern since, when a patient does not respond to available therapies, the prognosis is often grim. For example, the most common cancer in the UK and USA is breast cancer. The National Cancer Institute has published statistics for cancer in the USA numbers of new cases on breast cancer there in 2015 has been estimated to be 234,190 with 40,700 deaths [http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf]. Cancer Research UK also publishes statistics for the UK with 331,487 new diagnoses of cancer in 2011 with cancers of the breast, prostate, lung and bowel accounting for over half that number. In the same article, the authors reported 50,285 new cases of breast cancer and 11,716 deaths from breast cancer in 2011 [http://www.cancerresearchuk.org/health-professional/cancer-statistics#heading-Zero]. Patients with many cancers including breast cancer develop resistance to the medicines used during treatment. For example, Tamoxifen resistance occurs in about 25% of patients undergoing treatment. Tamoxifen is an antagonist of the estrogen receptor in breast tissue and is a drug of considerable importance in breast cancer therapy. In the area of infectious disease, bacterial resistance to common antibiotics is widely reported in the general press with harrowing accounts of Vancomycin Resistant Enterococci or Methicillin-resistant Staphylococcus aureus infections with clinical manifestations such as Necrotizing fasciitis (flesh eating disease). The emergence of resistance amongst cohorts of patients is a major driver for the discovery and development of new medicines to treat cancer and bacterial infections amongst other diseases.In 2014, scientists in the Vertex company [http://pubs.acs.org/doi/abs/10.1021/jm500941m] reported that natural products are again very appropriate to study and derivatise by chemical transformations in order to prepare new bioactive compounds for assay and optimization as the anti-cancer agents and antibiotics of tomorrow. In this article, they reported that from January 1981 to December 2010, 540 out of 1073 of the new drugs introduced were either natural products, derivatives of natural products or were structurally related to natural products (bioinspired) but made by chemical synthesis. By way of examples, the authors described the importance of natural product leads for Docetaxel, which is a derivative of paclitaxel used to treat diverse cancers, and Ixabepilone, which is an analogue of epothilone B used to treat taxol-resistant cancers, amongst many other examples. The focus of this research proposal is the design and development of four new chemical transformations, which have been invented at Imperial College, for the synthesis of a class of natural products, the meroterpenoids. The meroterpenoids are a structurally diverse series noted for diverse bioactivities as antibiotics and as anti-cancer agents, etc. In general, these compounds are active but insufficiently active to be drugs in their own right. In pharmaceutical terminology they are hits not leads. In order for the synthesis of a complex natural product such as a meroterpenoids to be practical, it is necessary that the synthetic route is short and amenable to parallel synthesis directed by bioassay results and computer assisted drug design to produce pharmaceutical leads. The Imperial team now has the necessary synthetic tools to make structure activity studies and bring new drug discovery based on the meroterpenoids within reach. In the research, the new Imperial chemical reactions will be employed with other transformations including selective oxidation and cyclisation reactions (forming additional rings) to open up the area of the meroterpenoids to rational medicinal chemistry and drug discovery.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Synthesis, Aromatization and Derivatization Reactions of 2-[9-( tert -Butoxycarbonyl)-4-oxo-1,5-dioxa-9-azaspiro[5.5]undec-2-en-2-yl]acetic Acid
2-[9-(叔丁氧基羰基)-4-氧代-1,5-二氧杂-9-氮杂螺[5.5]十一碳-2-烯-2-基]乙酸的合成、芳构化和衍生化反应
DOI: 10.1002/ejoc.201901451
发表时间: 2019
期刊: European Journal of Organic Chemistry
影响因子: 2.8
作者: [Ma T]
通讯作者: Ma T
DOI: 10.1158/1535-7163.mct-16-0847
发表时间: 2018-06
期刊: Molecular cancer therapeutics
影响因子: 5.7
作者: [Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S]
通讯作者: Ali S
Correction to "A Simple, Short, and Flexible Synthesis of Viridiofungin Derivatives".
对“Viridiofungin 衍生物的简单、简短且灵活的合成”的更正。
DOI: 10.1021/acs.joc.9b01172
发表时间: 2019
期刊: The Journal of organic chemistry
影响因子: --
作者: [Goldup SM]
通讯作者: Goldup SM
Front Cover: Synthesis, Aromatization and Derivatization Reactions of 2-[9-( tert -Butoxycarbonyl)-4-oxo-1,5-dioxa-9-azaspiro[5.5]undec-2-en-2-yl]acetic Acid (Eur. J. Org. Chem. 1/2020)
封面:2-[9-(叔丁氧基羰基)-4-氧代-1,5-二氧杂-9-氮杂螺[5.5]undec-2-en-2-基]乙酸的合成、芳构化和衍生化反应(
DOI: 10.1002/ejoc.201901831
发表时间: 2019
期刊: European Journal of Organic Chemistry
影响因子: 2.8
作者: [Ma T]
通讯作者: Ma T
Group 2: Elements of 21st Century Catalysis
  • 批准号:
    EP/I014853/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $42.87万
  • 财政年份:
    2011
  • 负责人:
    Tony Barrett
  • 依托单位:
Concise Syntheses of Vinylcitrate, Isocitrate and Citrafungin A, a Potent Inhibitor of Fungal Geranylgeranyltranferase I
  • 批准号:
    EP/E033792/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $12.62万
  • 财政年份:
    2007
  • 负责人:
    Tony Barrett
  • 依托单位:
The Development of Inhibitors of Cdk Activating Kinase (CAK)
  • 批准号:
    EP/F008856/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $12.31万
  • 财政年份:
    2007
  • 负责人:
    Tony Barrett
  • 依托单位:
Two Directional Benzyne Ring Annulation in the Total Synthesis of Sch 47554
  • 批准号:
    EP/E047432/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $35.62万
  • 财政年份:
    2007
  • 负责人:
    Tony Barrett
  • 依托单位:
海外基金